Earlier this week, the United States Food and Drug Administration (FDA) approved a human trial for a blueberry-sized brain ...

In April 2026, COMPASS Pathways announced that the FDA granted a rolling NDA review for its synthetic psilocybin therapy COMP360 in treatment-resistant depression and selected it for the ...

The newly approved device aims to treat depression by directly stimulating neural activity.

The FDA’s move follows an executive order from President Donald Trump earlier this month that paved the way for more ...

Brain implant gets FDA clearance for first wireless depression treatment trial, offering battery-free stimulation in ...

Curio Digital Therapeutics Inc.’s MamaLife Plus offers a nonpharmaceutical alternative to treating postpartum depression. Last month, it because the first prescription digital therapeutic (PDT) ...

The move comes less than a week later after President Donald Trump signed an executive order to extend research to study ...

TRENTON, N.J. (AP) — The U.S. Food and Drug Administration has approved the first drug specifically developed for severe depression after childbirth. The agency on Tuesday approved Sage Therapeutics' ...

Scientists at Weill Cornell Medicine say they’ve identified how ketamine produces its rapid antidepressant effects — a ...

A device the size of a blueberry is hypothesized to give people with treatment-resistant depression another option — and the FDA is giving its Houston maker a chance to test it.

NEW YORK (WPIX) – The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday. Spravato is a first-of-its-kind medication to help ...

The U.S. Food and Drug Administration has approved the expanded use of Johnson & Johnson‘s Caplyta as an add-on treatment for adults with major depressive disorder. Following the FDA’s Nov. 5 decision ...